Hypercalcemia of Malignancy
Elevated calcium in setting of known/suspected malignancy
All Pathways
EndocrinologyEmergency
Hypercalcemia of Malignancy Management
Hypercalcemia of Malignancy Management: Hypercalcemia of Malignancy → Assess Severity → Clinical Manifestations → 1. IV Fluid Resuscitation → Severity-B...
Pathway Overview
16 steps
Algorithm Steps
16 total
01Start 02Decision Assess Severity
Corrected calcium or ionized calcium
- Mild: Corrected Ca 10.5-12 mg/dL (2.6-3.0 mmol/L)
- Moderate: Corrected Ca 12-14 mg/dL (3.0-3.5 mmol/L)
- Severe: Corrected Ca >14 mg/dL (>3.5 mmol/L)
- Correction: Add 0.8 mg/dL for each 1 g/dL albumin below 4
03Action Clinical Manifestations
'Stones, bones, groans, moans, and psychic overtones'
- GI: Nausea, vomiting, constipation, anorexia, pancreatitis
- Neuro: Confusion, lethargy, weakness, coma
- Cardiac: Shortened QT, bradycardia, arrhythmias
- Renal: Polyuria, polydipsia, nephrolithiasis, AKI
- Musculoskeletal: Bone pain, weakness
04Action 1. IV Fluid Resuscitation
First-line treatment for all patients
- 0.9% Normal Saline 200-300 mL/hr initially
- Target: 3-6 L in first 24 hours
- Goal: Restore volume, enhance renal calcium excretion
- Adjust for cardiac/renal status
- Monitor for fluid overload
05Decision Severity-Based Treatment
Additional therapy based on calcium level
06Action SEVERE (Ca >14 mg/dL)
Calcitonin + IV bisphosphonate or denosumab
- Calcitonin 4 IU/kg IM/SubQ q12h for 48-72h
- Provides rapid (but transient) calcium lowering
- Tachyphylaxis develops in 48-72h
- PLUS long-acting agent (see next)
07Decision 2. Choose: IV Bisphosphonate vs Denosumab
Endocrine Society suggests denosumab over IV BP
08Action IV Bisphosphonate
Zoledronic acid preferred
- Zoledronic acid 4 mg IV over 15 min (preferred)
- OR Pamidronate 60-90 mg IV over 2-4 hours
- Onset: 2-4 days, Duration: 2-4 weeks
- Adjust for renal function (CrCl <30: avoid zoledronic)
- Can repeat in 7 days if needed
09Action Refractory/Recurrent HCM
Options for treatment-resistant cases
- If on bisphosphonate: Switch to denosumab
- If on denosumab: Add or switch to bisphosphonate
- Consider calcimimetic (cinacalcet) for parathyroid carcinoma
- Glucocorticoids for calcitriol-mediated HCM
- Dialysis for severe, refractory cases
10Action 3. Monitoring
Close follow-up during treatment
- Calcium: q6-12h initially, then daily
- Creatinine, electrolytes: daily
- Phosphorus: may decrease with bisphosphonates
- Watch for hypocalcemia (especially with denosumab)
- Fluid balance
11Outcome Calcium Controlled
Continue cancer treatment, monitor for recurrence
12Warning Palliative Considerations
End-stage malignancy, comfort care
- HCM may be terminal event
- Discuss goals of care
- Symptom management focus
13Action Denosumab
RANK-L inhibitor, suggested over bisphosphonates
- Denosumab 120 mg SubQ
- Onset: 2-4 days, Duration: 4 weeks
- Safe in renal impairment (no dose adjustment)
- Can give additional doses on days 8, 15, 29 for refractory cases
- CAUTION: Rebound hypercalcemia after discontinuation
- Path rejoins step 09Shared downstream outcome
14Warning ⚠️ Calcitriol-Mediated HCM
Lymphoma, granulomatous disease
- First-line: Glucocorticoids (prednisone 20-40 mg/day)
- Reduces calcitriol production by macrophages
- Add bisphosphonate/denosumab if glucocorticoids insufficient
15Action MODERATE (Ca 12-14 mg/dL)
IV bisphosphonate or denosumab
- Skip calcitonin unless very symptomatic
- Proceed directly to bisphosphonate or denosumab
- Path rejoins step 07Shared downstream outcome
16Action MILD (Ca 10.5-12 mg/dL)
Fluids, may not need additional therapy
- IV fluids often sufficient
- Consider bisphosphonate/denosumab if symptomatic
- Treat underlying malignancy
- Path rejoins step 10Shared downstream outcome
Guideline Source
Treatment of Hypercalcemia of Malignancy in Adults: Endocrine Society Clinical Practice Guideline
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address primary hyperparathyroidism management
- Denosumab requires monitoring for rebound hypercalcemia after discontinuation
- Bisphosphonates require renal dose adjustment
- Does not cover pediatric hypercalcemia
Contraindicated Populations
pediatric
Applicable Regions
USEU
EU: ESE co-sponsored these guidelines
US: Endocrine Society guideline, co-sponsored by ASBMR and ESE
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Hypercalcemia of Malignancy Management?
The Hypercalcemia of Malignancy Management is a emergency clinical algorithm for Endocrinology. It provides a structured decision tree to guide clinical decision-making, based on Treatment of Hypercalcemia of Malignancy in Adults: Endocrine Society Clinical Practice Guideline.
What guideline is the Hypercalcemia of Malignancy Management based on?
This algorithm is based on Treatment of Hypercalcemia of Malignancy in Adults: Endocrine Society Clinical Practice Guideline (DOI: 10.1210/clinem/dgac621).
What are the limitations of the Hypercalcemia of Malignancy Management?
Known limitations include: Does not address primary hyperparathyroidism management; Denosumab requires monitoring for rebound hypercalcemia after discontinuation; Bisphosphonates require renal dose adjustment; Does not cover pediatric hypercalcemia. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Hypercalcemia of Malignancy Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free